Immunotherapy News and Research

Latest Immunotherapy News and Research

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

Children with egg allergies who consume increasingly higher doses of egg protein - the very nutrient they react to - appear to gradually overcome their allergies, tolerating eggs better over time and with milder symptoms, according to research conducted at Johns Hopkins Children's Center and elsewhere.

1 Mar 2010

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer’s disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.

1 Mar 2010

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Complementary approaches to Alzheimer's research were recognized as four scientists received the prestigious MetLife Foundation Awards for Medical Research in Alzheimer's Disease in Washington, D.C.

26 Feb 2010

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.

25 Feb 2010

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.

25 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

New guidance document to prevent food allergies

For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.

19 Feb 2010

Advaxis reports net income of $929,244 for year ended October 31, 2009

Advaxis, Incorporated, the live, attenuated Listeria monocytogenes immunotherapy company, today reported results for the fiscal year-ended October 31, 2009.

19 Feb 2010

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.

16 Feb 2010

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

The beauty of budding plants and bouquet of aromas are sources of satisfaction for many gardeners. For allergy sufferers, though, gardening can be as much a chore as pursuit of passion.

15 Feb 2010

Ragweed pollen allergy: SLIT safe and effective alternative to injections

An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published today in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital.

15 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).

12 Feb 2010

Intellect Neurosciences: Several significant stakeholders commit funds

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that several of its significant shareholders (the "Interested Shareholders") have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet.

11 Feb 2010

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Highlights from the Lymphoma Research Foundation (LRF) 2009 Mantle Cell Lymphoma Consortium (MCLC) Scientific Workshop will be published in the March 2010 issue of Leukemia & Lymphoma. Traditionally accessible to subscribers for period of one year, Leukemia and Lymphoma has agreed to make this report available to the public for one month -- Mantle Cell Lymphoma: Report of the 2009 MCL Consortium Workshop.

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Northwest Biotherapeutics, Inc., a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development.

8 Feb 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

Phase III study results of Merck's allergy immunotherapy tablet

Oral immunotherapy promising for egg allergies, SLIT for milk allergies

[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

LGL awards first three grants from POC fund for research in immunotherapy, schizophrenia and heart disease

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

Study shows CEL-2000 vaccine blocks RA progression in mice

New guidance document to prevent food allergies

Advaxis reports net income of $929,244 for year ended October 31, 2009

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency

People can take simple steps to minimize risk of exposure to allergens during gardening, AAAAI

Ragweed pollen allergy: SLIT safe and effective alternative to injections

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

NewLink Genetics receives FDA SPA approval for HyperAcute immunotherapy Phase 3 pancreatic cancer trial

Intellect Neurosciences: Several significant stakeholders commit funds

LRF's 2009 Mantle Cell Lymphoma Consortium report published

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Immunotherapy News and Research

Latest Immunotherapy News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in